QNCX Profile
Quince Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing precision therapeutics aimed at treating debilitating and rare diseases. The company's innovative approach centers on a bone-targeting drug platform designed to deliver therapeutic agentsâ€whether small molecules, peptides, or larger biomoleculesâ€directly to the site of bone fractures and disease. This technology is intended to enhance the efficacy of treatments for bone-related conditions by ensuring targeted delivery and reducing systemic side effects.
Quince Therapeutics' lead compound, NOV004, represents a key advancement in the company's therapeutic portfolio. NOV004 is an anabolic peptide engineered to specifically target and concentrate at the site of bone fractures. This targeted approach aims to accelerate bone healing and improve outcomes for patients with fractures or other bone diseases. The development of NOV004 reflects the company’s commitment to addressing significant unmet medical needs in the field of bone health.
In addition to NOV004, Quince Therapeutics is advancing a range of other therapeutic candidates through its proprietary bone-targeting platform. The company's research and development efforts focus on expanding the applicability of this technology to various bone-related conditions, including osteoporosis and other degenerative bone diseases. Quince Therapeutics is also exploring potential applications of its platform for rare and challenging diseases that lack effective treatments.
Founded in 2012 and headquartered in South San Francisco, California, Quince Therapeutics, Inc. was formerly known as Cortexyme, Inc. The company rebranded to Quince Therapeutics in August 2022 to better reflect its strategic focus on bone-targeting therapeutics. With a robust pipeline and a dedication to precision medicine, Quince Therapeutics is well-positioned to make significant contributions to the treatment of bone and rare diseases, leveraging its innovative platform to advance patient care.
|
